Search research articles
Contact Us
Filters
Showing results (11-20 of 395) with videos related to
Page
of 40
Sort By:
Brain : a Journal of Neurology
|
March 4, 2016
Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
Sebastian Palmqvist, Niklas Mattsson, Oskar Hansson, et al.
International Journal of Alzheimer'S Disease
|
August 28, 2010
To know or not to know: ethical issues related to early diagnosis of Alzheimer's disease
Niklas Mattsson, David Brax, Henrik Zetterberg
Brain : a Journal of Neurology
|
July 8, 2016
Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?
Sebastian Palmqvist, Niklas Mattsson, Oskar Hansson
Lakartidningen
|
July 6, 2004
[Helicobacter pylori can in rare cases be the cause of iron and vitamin B 12 deficiency. No increased risk of iron and vitamin B 12 deficiency due to proton pump inhibitors]
Niklas Mattsson, Anders Kilander, Einar Björnsson
Clinical Chemistry and Laboratory Medicine
|
March 6, 2010
Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall
Niklas Mattsson, Kaj Blennow, Henrik Zetterberg
International Journal of Alzheimer'S Disease
|
August 20, 2010
Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
Niklas Mattsson, Henrik Zetterberg, Kaj Blennow
International Journal of Alzheimer'S Disease
|
April 14, 2011
Cerebrospinal fluid analysis should be considered in patients with cognitive problems
Henrik Zetterberg, Niklas Mattsson, Kaj Blennow
Annals of the New York Academy of Sciences
|
November 13, 2009
CSF biomarkers: pinpointing Alzheimer pathogenesis
Niklas Mattsson, Kaj Blennow, Henrik Zetterberg
Cell Reports. Medicine
|
September 18, 2024
Integrating amyloid and tau imaging with proteomics and genomics in Alzheimer's disease
Gabriele Vilkaite, Jacob Vogel, Niklas Mattsson-Carlgren
Alzheimer'S Research & Therapy
|
December 3, 2010
Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
Henrik Zetterberg, Niklas Mattsson, Kaj Blennow, et al.
Page
of 40
Search research articles
Search
Showing results (11-20 of 395) with videos related to
Sort By:
Page
of 40
Brain : a Journal of Neurology
|
March 4, 2016
Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
Sebastian Palmqvist, Niklas Mattsson, Oskar Hansson, et al.
International Journal of Alzheimer'S Disease
|
August 28, 2010
To know or not to know: ethical issues related to early diagnosis of Alzheimer's disease
Niklas Mattsson, David Brax, Henrik Zetterberg
Brain : a Journal of Neurology
|
July 8, 2016
Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?
Sebastian Palmqvist, Niklas Mattsson, Oskar Hansson
Lakartidningen
|
July 6, 2004
[Helicobacter pylori can in rare cases be the cause of iron and vitamin B 12 deficiency. No increased risk of iron and vitamin B 12 deficiency due to proton pump inhibitors]
Niklas Mattsson, Anders Kilander, Einar Björnsson
Clinical Chemistry and Laboratory Medicine
|
March 6, 2010
Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall
Niklas Mattsson, Kaj Blennow, Henrik Zetterberg
International Journal of Alzheimer'S Disease
|
August 20, 2010
Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
Niklas Mattsson, Henrik Zetterberg, Kaj Blennow
International Journal of Alzheimer'S Disease
|
April 14, 2011
Cerebrospinal fluid analysis should be considered in patients with cognitive problems
Henrik Zetterberg, Niklas Mattsson, Kaj Blennow
Annals of the New York Academy of Sciences
|
November 13, 2009
CSF biomarkers: pinpointing Alzheimer pathogenesis
Niklas Mattsson, Kaj Blennow, Henrik Zetterberg
Cell Reports. Medicine
|
September 18, 2024
Integrating amyloid and tau imaging with proteomics and genomics in Alzheimer's disease
Gabriele Vilkaite, Jacob Vogel, Niklas Mattsson-Carlgren
Alzheimer'S Research & Therapy
|
December 3, 2010
Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
Henrik Zetterberg, Niklas Mattsson, Kaj Blennow, et al.
Page
of 40